Pharmacotherapy of angina pectoris

Abstract

The key to the normal functioning of the heart muscle is the delivery of metabolites to it with blood, primarily oxygen, corresponding to the needs. When the balance between the supply of oxygen to the heart and its demand is imbalanced, myocardial ischemia occurs. This condition is a central link in the pathogenesis of the so-called coronary or ischemic heart disease (IHD). In 89–94% of patients with coronary artery disease, it is caused by atherosclerosis of the coronary arteries and aorta [15, 21, 26]. Regarding the pathogenetic treatment of chronic forms of coronary artery disease (CHD), namely angina pectoris, one should dwell on such points as the normalization of the psychoemotional sphere (tranquilizers), an increase in coronary blood flow and oxygen delivery (coronary active agents, β-adrenoactivators), a decrease in myocardial oxygen demand (R -adrenergic blockers, cordarone, calcium antagonists), redistribution of coronary blood flow from non-ischemic zones to ischemic zones (β-blockers), hemodynamic restructuring (nitrates), switching myocardial metabolism to a reserve anaerobic pathway (gliosiz, nonahlazine), effect on blood circulation antibiotics ). All these agents used for the treatment of angina pectoris are called antianginal drugs and in some cases can be combined with analgesics, cardiac glycosides, anticoagulants, antiarrhythmic, lipid-lowering and other drugs for the complex treatment of IBO.

Keywords

Kazan Medical archive

References

[1] Волков В. С., Бра то любое В. И. Казанский мед. ж., 1981, 3.

[2] Гасилин В. С., Сидоренко Б. А. Стенокардия. М., Медицина, 1981.

[3] Горлин Р. Болезни коронарных артерий. М., Медицина, 1980.

[4] Зимин Ю. В., Эсенбаева 3. М. Кардиология, 1981, 8.

[5] Каверина И. В., Розонов Ю. Б., Чичка> нов Г. Г. Современные аспекты фармакологии антиангинальных средств. М., Медицина, 1980.

[6] Лещинский Л. А., Шинкарева И. А. Клин, мед., 1976, 4.

[7] Лоример А. Р. В кн.: Стенокардия. М., Медицина, 1980.

[8] Малая Л. Т., Власенко М. А., Микляев И. Ю. Инфаркт миокарда. М., Медицина, 1981.

[9] Машковский М. Д. Лекарственные средства. М., Медицина, 1977.

[10] Метелица В. И. Справочник кардиолога по клинической фармакологии. М., Медицина, 1980.

[11] Преображенский Д. В., Рындина М. Г., Близи я к Г. В. Кардиология, 1979, 4.

[12] Райек и й В. А., Касаткина Л. В., Григорьянц Р. А., Прокудин В. Н„ Тер. арх., 1976, 6.

[13] Тополя некий В. Д., Альперович Б. Р. Там же, 1977, 9.

[14] Фултон-М., Джулиан Д. Г. В кн.: Стенокардия. М., Медицина, 1980.

[15] Шхвацабая И. К. Ишемическая болезнь сердца. М., Медицина, 1975.

[16] Fleckenstein A. Med. Klin., 1975, 70, 42,

[17] Kimura Е-, Kishida H. Circulation, 1981, 63, 4.

[18] Mahr II. Herz Kreislauf, 1978, 10. 5.

[19] Mason D. T., Miller R. R., Amsterdam E. A. In.: Beta-adrenoceptor blocking agents. Amsterdam, 1976.

[20] Murell W. Lancet, 1879, 1, 1.

[21] Parratt J. R. Adv. Drug Res., 1974, 9.

[22] Prichard B. N. Postgrad. Med. J., 1976, 52, 4.

[23] iRupprecht E. Z. Allgem'einmed., 1977, 53, 17.

[24] Schaper W. Medikon, 1975, 4, I.— 25. ShimamоtоT. In.: Cardiovascular Disease. Urban and Schwarzenberg, 1974.Stump J. M., Vernier V. G. In.: New Drugs. Discovery and Develop. New York — Basel, 1978.

[25] Waters D D., Sz1achcic J., Theroux P. Dau- we F., Mizga I a H. F. Am. J. Cardiol., 1981, 47, 1.

RIGHTS & PERMISSIONS

Camburg R.A.